Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Lung Cancer

  Free Subscription


24.02.2020

1 Ann Oncol
3 Anticancer Res
1 Br J Cancer
5 Cancer Sci
1 Clin Cancer Res
2 Clin Nucl Med
3 Int J Cancer
2 Int J Radiat Oncol Biol Phys
3 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Nucl Med
1 J Surg Oncol
16 J Thorac Cardiovasc Surg
1 JAMA Oncol
2 Lung Cancer
1 Mol Carcinog
1 N Engl J Med
1 Oncologist
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. GAINOR JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, et al
    Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression >/=50.
    Ann Oncol. 2020;31:404-411.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. KASHIWABARA K, Fuji S, Tsumura S, Sakamoto K, et al
    Prognosis of EGFR-mutant Lung Adenocarcinoma Patients With Malignant Pleural Effusion Receiving First-line EGFR-TKI Therapy Without Pleurodesis: A Single-institute Retrospective Study.
    Anticancer Res. 2020;40:1117-1121.
    PubMed     Text format     Abstract available

  3. NIEDER C, Dalhaug A, Pawinski A
    Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy.
    Anticancer Res. 2020;40:977-981.
    PubMed     Text format     Abstract available

  4. OKAUCHI S, Numata T, Nawa T, Ichimura H, et al
    Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.
    Anticancer Res. 2020;40:957-964.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. GIATROMANOLAKI A, Harris AL, Banham AH, Contrafouris CA, et al
    Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-020-0756.
    PubMed     Text format     Abstract available


    Cancer Sci

  6. ZHANG Y, Du H, Li Y, Yuan Y, et al
    Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.
    Cancer Sci. 2020;111:637-646.
    PubMed     Text format     Abstract available

  7. YE L, Jia K, Wang L, Li W, et al
    CD137, an attractive candidate for the immunotherapy of lung cancer.
    Cancer Sci. 2020 Feb 19. doi: 10.1111/cas.14354.
    PubMed     Text format     Abstract available

  8. SHIMADA Y, Kudo Y, Maehara S, Matsubayashi J, et al
    Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
    Cancer Sci. 2020;111:610-620.
    PubMed     Text format     Abstract available

  9. SHIMA T, Shimoda M, Shigenobu T, Ohtsuka T, et al
    Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Cancer Sci. 2020;111:727-738.
    PubMed     Text format     Abstract available

  10. ZHANG S, Li G, Liu C, Lu S, et al
    miR-30e-5p represses angiogenesis and metastasis by directly targeting AEG-1 in squamous cell carcinoma of the head and neck.
    Cancer Sci. 2020;111:356-368.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  11. LI X, Zhang L, Jiang D, Wang Y, et al
    Routine-dose and High-dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients harboring EGFR Exon 21 L858R Mutation: the Randomized, Phase II, INCREASE Trial.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-3064.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  12. NGUYEN NC, Muthukrishnan A, Mountz JM
    Differential 18F-FDG and 18F-Fluciclovine Uptake Pattern in a Patient With Poorly Differentiated Adenocarcinoma of the Lung and Prostate Cancer Biochemical Recurrence.
    Clin Nucl Med. 2020;45:e63-e64.
    PubMed     Text format     Abstract available

  13. ZHANG J, Kulkarni HR, Singh A, Baum RP, et al
    Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
    Clin Nucl Med. 2020;45:e48-e50.
    PubMed     Text format     Abstract available


    Int J Cancer

  14. JIN R, Li J, Jin Z, Lu Y, et al
    Osimertinib confers potent binding affinity to EGFR kinase domain duplication.
    Int J Cancer. 2019;145:2884-2885.
    PubMed     Text format    

  15. TANG D, Zhao YC, Liu H, Luo S, et al
    Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the Ketone pathway and survival of non-small cell lung cancer.
    Int J Cancer. 2020 Feb 18. doi: 10.1002/ijc.32932.
    PubMed     Text format     Abstract available

  16. HATA A, Nakajima T, Matsusaka K, Fukuyo M, et al
    A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.
    Int J Cancer. 2020;146:388-399.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  17. SALEEM A, Helo Y, Win Z, Dale R, et al
    Integrin alphavbeta6 positron emission tomography imaging in lung cancer patients treated with pulmonary radiotherapy.
    Int J Radiat Oncol Biol Phys. 2020 Feb 11. pii: S0360-3016(20)30184.
    PubMed     Text format     Abstract available

  18. KAMRAVA M, Chino JP, Beriwal S
    SAbR as an Alternative Boost Modality for Cervical Cancer: A Cautionary Exercise.
    Int J Radiat Oncol Biol Phys. 2020;106:472-474.
    PubMed     Text format    


    J Cancer Res Clin Oncol

  19. TANG Y, Che N, Yu Y, Gao Y, et al
    Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
    J Cancer Res Clin Oncol. 2020;146:407-416.
    PubMed     Text format     Abstract available

  20. QIANG H, Chang Q, Xu J, Qian J, et al
    New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Feb 17. pii: 10.1007/s00432-020-03129.
    PubMed     Text format     Abstract available

  21. LANDRE T, Des Guetz G, Chouahnia K, Taleb C, et al
    First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
    J Cancer Res Clin Oncol. 2020;146:441-448.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study.
    J Clin Oncol. 2020 Feb 20:JCO1902446. doi: 10.1200/JCO.19.02446.
    PubMed     Text format     Abstract available


    J Nucl Med

  23. HUISMAN M, Niemeijer AL, Windhorst B, Schuit R, et al
    Quantification of PD-L1 expression with [(18)F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2020 Feb 14. pii: jnumed.119.240895. doi: 10.2967/jnumed.119.240895.
    PubMed     Text format     Abstract available


    J Surg Oncol

  24. CORSINI EM, Datar SS, Mitchell KG, Zhou N, et al
    High mutational concordance between primary colorectal tumors and associated pulmonary metastases.
    J Surg Oncol. 2020 Feb 19. doi: 10.1002/jso.25871.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  25. CERFOLIO RJ
    Commentary: Do we have the right combatants? Should it be minimally invasive surgery versus therapy that removes no lymph nodes?
    J Thorac Cardiovasc Surg. 2019;158:1467-1468.
    PubMed     Text format    

  26. MOLINA JC, Liberman M
    Commentary: Pulling an entire lung out of a small incision-Video-assisted thoracoscopic surgical pneumonectomy, the final frontier in minimally invasive thoracic surgery.
    J Thorac Cardiovasc Surg. 2019;158:267-268.
    PubMed     Text format    

  27. DUX J, Grosser R, Adusumilli PS
    Commentary: Return to intended radiation therapy-Criteria for resection?
    J Thorac Cardiovasc Surg. 2019;158:930-931.
    PubMed     Text format    

  28. BOTT MJ
    Commentary: Cell proliferation and immune evasion: A dangerous combination.
    J Thorac Cardiovasc Surg. 2019;158:920-921.
    PubMed     Text format    


  29. Discussion.
    J Thorac Cardiovasc Surg. 2019;157:1231-1235.
    PubMed     Text format    

  30. YANG CJ, Berry MF
    Commentary: Resection of clinical early-stage lung cancer with unexpected nodal disease-can less really be the same?
    J Thorac Cardiovasc Surg. 2019 Dec 26. pii: S0022-5223(19)41495.
    PubMed     Text format    

  31. ITO H, Suzuki K, Mizutani T, Aokage K, et al
    Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jan 11. pii: S0022-5223(20)30054.
    PubMed     Text format     Abstract available

  32. BOYS J, Onaitis M
    Commentary: Breaking down non-small cell lung cancer tumor microenvironment heterogeneity and predicting response to immune checkpoint inhibitors.
    J Thorac Cardiovasc Surg. 2019 Dec 16. pii: S0022-5223(19)36852.
    PubMed     Text format    

  33. CHIDI A, Broderick SR
    Commentary: Chemo if you can-disparities in receipt of guideline-concordant adjuvant therapy in patients with locoregional non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2020 Jan 3. pii: S0022-5223(19)43489.
    PubMed     Text format    

  34. SIHAG S
    Commentary: Surgery for N3 disease: Next frontier or has this ship already sailed?
    J Thorac Cardiovasc Surg. 2019;158:1695-1697.
    PubMed     Text format    

  35. YANG SC
    Discussion.
    J Thorac Cardiovasc Surg. 2019;158:1675-1677.
    PubMed     Text format    

  36. BERRY MF
    Discussion.
    J Thorac Cardiovasc Surg. 2019;158:1465-1466.
    PubMed     Text format    

  37. HUANG J
    Discussion.
    J Thorac Cardiovasc Surg. 2019;158:1691-1692.
    PubMed     Text format    

  38. GONZALEZ-RIVAS D, Rami-Porta R
    Commentary: Intraoperative lymph node assessment by robotic, video-assisted thoracoscopic surgery, and thoracotomy: None meet the international recommendations.
    J Thorac Cardiovasc Surg. 2019;158:1469-1470.
    PubMed     Text format    


  39. Discussion.
    J Thorac Cardiovasc Surg. 2019;158:1240-1241.
    PubMed     Text format    

  40. LIU R, Kidane B
    Commentary: Detection is only part of the equation-Does elevated risk alone warrant screening?
    J Thorac Cardiovasc Surg. 2019;158:1255-1256.
    PubMed     Text format    


    JAMA Oncol

  41. JABBOUR SK, Berman AT, Decker RH, Lin Y, et al
    Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2020 Feb 20. pii: 2761665. doi: 10.1001/jamaoncol.2019.6731.
    PubMed     Text format     Abstract available


    Lung Cancer

  42. SERRA P, Centeno C, Sanz-Santos J, Torky M, et al
    Is it necessary to sample the contralateral nodal stations by EBUS-TBNA in patients with lung cancer and clinical N0 / N1 on PET-CT?
    Lung Cancer. 2020;142:9-12.
    PubMed     Text format     Abstract available

  43. JOHNSON AM, Johnson A, Hines RB, Mohammadi R, et al
    Neighborhood context and non-small cell lung cancer outcomes in Florida non-elderly patients by race/ethnicity.
    Lung Cancer. 2020;142:20-27.
    PubMed     Text format     Abstract available


    Mol Carcinog

  44. WANG B, Pan LY, Kang N, Shen XY, et al
    PP4R1 interacts with HMGA2 to promote non-small-cell lung cancer migration and metastasis via activating MAPK/ERK-induced epithelial-mesenchymal transition.
    Mol Carcinog. 2020 Feb 19. doi: 10.1002/mc.23168.
    PubMed     Text format     Abstract available


    N Engl J Med

  45. D'SILVA K, Cockrill B, Anderson WJ, Miller AL, et al
    A Rapid Change in Pressure.
    N Engl J Med. 2020;382:563-570.
    PubMed     Text format    


    Oncologist

  46. JIANG S, Liang H, Liu Z, Zhao S, et al
    The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).
    Oncologist. 2020 Feb 20. doi: 10.1634/theoncologist.2019-0838.
    PubMed     Text format     Abstract available


    PLoS One

  47. ELLIOTT J, Bai Z, Hsieh SC, Kelly SE, et al
    ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    PLoS One. 2020;15:e0229179.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: